Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
After ZW171's exit, ZW251 enters the clinic.
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
The UK company buys IRDx for $1bn.
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
